These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 12270321)
1. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. Colak T; Karakayali H; Yagmurdur MC; Moray G Transplant Proc; 2002 Sep; 34(6):2081-2. PubMed ID: 12270321 [No Abstract] [Full Text] [Related]
2. Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. Kohnle M; Zimmermann U; Lütkes P; Albrecht KH; Philipp T; Heemann U Transpl Int; 2000; 13 Suppl 1():S345-8. PubMed ID: 11112029 [TBL] [Abstract][Full Text] [Related]
3. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Friemann S; Feuring E; Padberg W; Ernst W Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504 [No Abstract] [Full Text] [Related]
4. Conversion to tacrolimus in hyperlipidemic patients. Friemann S; Stopp K; Christ B; Weimer R; Padberg W; Ernst W Transplant Proc; 1999 Nov; 31(7A):41S-43S. PubMed ID: 10576042 [No Abstract] [Full Text] [Related]
5. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. Copley JB; Staffeld C; Lindberg J; Hansen A; Bailey C; Anand R; Van Veldhuisen P Transplant Proc; 1998 Jun; 30(4):1254-6. PubMed ID: 9636510 [No Abstract] [Full Text] [Related]
6. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Busque S; Demers P; St-Louis G; Boily JG; Tousignant J; Lemieux F; Smeesters C; Corman J; Daloze P Transplant Proc; 1998 Jun; 30(4):1247-8. PubMed ID: 9636507 [No Abstract] [Full Text] [Related]
7. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience. Manu M; Tanabe K; Tokumoto T; Ishikawa N; Shimizu T; Okuda H; Ito S; Shimmura H; Inui M; Harano M; Shiroyanagi Y; Yagisawa T; Fuchinoue S; Toma H Transplant Proc; 2000 Nov; 32(7):1736-8. PubMed ID: 11119912 [No Abstract] [Full Text] [Related]
8. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Jurewicz WA Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048 [No Abstract] [Full Text] [Related]
9. Conversion to tacrolimus in case-problem kidney transplant recipients under cyclosporine-based immunosuppression. Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimaräes S Transplant Proc; 2000 Dec; 32(8):2636-8. PubMed ID: 11134735 [No Abstract] [Full Text] [Related]
10. Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. Dudley CR; Transplant Proc; 2001; 33(1-2):1034-5. PubMed ID: 11267179 [No Abstract] [Full Text] [Related]
11. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. McCune TR; Thacker LR II; Peters TG; Mulloy L; Rohr MS; Adams PA; Yium J; Light JA; Pruett T; Gaber AO; Selman SH; Jonsson J; Hayes JM; Wright FH; Armata T; Blanton J; Burdick JF Transplantation; 1998 Jan; 65(1):87-92. PubMed ID: 9448150 [TBL] [Abstract][Full Text] [Related]
12. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494 [No Abstract] [Full Text] [Related]
13. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357 [No Abstract] [Full Text] [Related]
14. Conversion from cyclosporine to tacrolimus is preferred by pediatric renal transplant recipients: a focus on opinions and outcomes. Sundberg AK; Smith LD; Somerville KT; Cox R; Sherbotie JR Transplant Proc; 2002 Aug; 34(5):1951-2. PubMed ID: 12176640 [No Abstract] [Full Text] [Related]
15. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus? Gelens MA; Christiaans MH; v Hooff JP Transplant Proc; 2005 May; 37(4):1900-1. PubMed ID: 15919498 [TBL] [Abstract][Full Text] [Related]
16. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. Boratyńska M; Banasik M; Patrzałek D; Klinger M Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290 [TBL] [Abstract][Full Text] [Related]
17. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. Pohanka E; Margreiter R; Sparacino V; Sperschneider H; Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490 [TBL] [Abstract][Full Text] [Related]
18. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233 [No Abstract] [Full Text] [Related]
19. Rescue therapy with tacrolimus in renal graft patients with cyclosporine A-induced hepatotoxicity: a preliminary study. Yuan QS; Zheng FL; Sun Y; Yu Y; Li Y Transplant Proc; 2000 Nov; 32(7):1694-5. PubMed ID: 11119896 [No Abstract] [Full Text] [Related]